RAYALDEE® (calcifediol)
Secondary Hyperparathyroidism in CKD
MarketCommercial
Key Facts
About Opko Health
OPKO Health is a unique, fully-integrated biopharmaceutical and diagnostics company founded in 2007. Its core strategy combines the steady, high-volume revenue of its BioReference Laboratories diagnostics business with targeted therapeutic R&D in multispecific antibodies and long-acting delivery technologies. Key achievements include the global commercialization of NGENLA™ (somatrogon) with Pfizer and the marketing of RAYALDEE® for secondary hyperparathyroidism, while its research subsidiary, ModeX Therapeutics, advances a novel pipeline with partners like Merck and Regeneron. This hybrid model aims to de-risk drug development while pursuing transformative medicines for complex diseases.
View full company profile